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Abstract
Microglia have diverse actions, ranging from synapse pruning in development to cytotoxic effects
in disease. Brain energy metabolism and substrate availability vary under normal and disease states,
but how these variations influence microglial function is relatively unknown. Microglia, like most
other cell types, express the full complement of gene products required for both glycolytic and oxi-
dative metabolism. Evidence suggests that microglia increase aerobic glycolysis and decrease
respiration when activated by various stimuli. Mitochondrial function, glucose availability, and gly-
colytic rate influence pro-inflammatory gene expression at both transcriptional and post-
translational levels. These effects are mediated through CtBP, an NADH—sensitive transcriptional
co-repressor; through effects on NLRP3 inflammasome assembly and caspase-1 activation;
through formation of advanced glycation end-products; and by less well-defined mechanisms. In
addition to these transcriptional effects, microglial glucose metabolism is also required for superox-
ide production by NADPH oxidase, as glucose is the obligate substrate for regenerating NADPH in
the hexose monophosphate shunt. Microglia also metabolize acetoacetate and b-hydroxybutyrate,
which are generated during fasting or ketogenic diet, and respond to these ketones as metabolic
signals. b-Hydroxybutyrate inhibits histone de-acetylases and activates microglial GRP109A recep-
tors. These actions suppress microglia activation after brain injury and promote neuroprotective
microglia phenotypes. As our understanding of microglial activation matures, additional links
between energy metabolism and microglial function are likely to be identified.
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1 | INTRODUCTION
Microglia are resident immune cells of the central nervous system
(CNS), closely related to dendritic cells found in other tissues and to
circulating macrophages. Microglia express an array of immune mole-
cules, including toll like receptors, integrins such as CD11b,
nucleotide-binding oligomerization domain receptors (NLRs), and trig-
gering receptor expressed on myeloid cells (TREM; Derecki, Katzmar-
ski, Kipnis, & Meyer-Luehmann, 2014; Hsieh et al., 2009;
Nimmerjahn, Kirchhoff, & Helmchen, 2005; Parkhurst & Gan, 2010).
Microglia secrete trophic factors, release proteases required for
remodeling extracellular matrix, and phagocytize cells or parts of cells
that are destined for destruction (Fourgeaud et al., 2016; Nakanishi,
2003; Schafer et al., 2012; Tremblay, Lowery, & Majewska, 2010;
Wake, Moorhouse, Jinno, Kohsaka, & Nabekura, 2009). Consistent
with their immune cell lineage, microglia also act as detectors of
infection and injury, and rapidly respond to these events. This pat-
terned response is generally termed “microglial activation” and
involves retraction of processes, migration to sites of injury, and the
release of proteases, reactive oxygen species (ROS) and cytokines
(Davalos et al., 2012; Ghosh & Geahlen, 2015; Kettenmann, Hanisch,
Noda, & Verkhratsky, 2011; Vasek et al., 2016). These responses
serve as an innate first line response to infection, but in conditions
such as stroke and neurodegenerative disorders the cytotoxic aspects
of this innate response may have a net negative effect on outcome
(Banati, Gehrmann, Schubert, & Kreutzberg, 1993; Kobayashi,
Konishi, Takai, & Kiyama, 2015; Lehnardt, 2010).
Mechanisms by which inflammation affects cell energy metabolism
are now well established (Hotamisligil, 2006), but much less is known
about how energy metabolism affects inflammatory responses. The
issue is important because many disorders are accompanied by changes
in brain energy metabolism (Beal, 1995; Bergsneider et al., 1997; Ding,
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Yao, Rettberg, Chen, & Brinton, 2013; Dusick et al., 2007; Orth & Scha-
pira, 2002; Robbins & Swanson, 2014). Here we review current under-
standing of microglial energy metabolism and how energy metabolism
influences microglial function.
2 | ENERGY SUBSTRATES IN NORMAL AND
INJURED CNS
The central nervous system is unique in requiring a continuous supply
of glucose for normal function. All other tissues, including the heart,
can readily metabolize fatty acids, amino acids, and ketones in place of
glucose substrate, but the blood brain barrier prevents rapid influx of
these alternative substrates under most conditions (Siesj€o, 1978). Glu-
cose is metabolized almost completely to CO2 in normal brain. There
can be transient increase in glucose metabolism to lactate in response
to local brain activity, but the lactate thus produced is subsequently
metabolized oxidatively, or else escapes into the venous system
(Dienel, 2012). Blood glucose concentrations are normally 4–6 mMol/
L, essentially all of which can be extracted by brain. Normal, fully oxy-
genated blood carries 9 mmol/L O2, of which only a portion can be
extracted (Siesj€o, 1978). There is a glucose concentration gradient
between blood and brain, with normal cerebrospinal fluid glucose val-
ues in the range of 2–3 mMol/L, and normal extracellular glucose val-
ues being about 1.5 mMol/L. There is similarly a gradient to oxygen,
with brain parenchyma containing about 2 mMol/L O2. Since 6 moles
of O2 are required to oxidize each mole of glucose, this leaves a large
excess of glucose available for anaerobic metabolism to lactate when
blood delivery of oxygen falls short of demand. This can occur during
hypoxia, but also occurs in conditions such as stroke, brain trauma, and
increased intracranial pressure. Under these conditions, the rate of glu-
cose utilization in the ischemic brain can be increased by elevated
blood glucose concentration (hyperglycemia). The resulting anaerobic
glucose metabolism can generate substantial amounts of ATP, but also
produces lactic acid (as occurs normally in exercising muscle).
With reductions in blood glucose, as occur during fasting or stren-
uous exercise, the ketones acetoacetate and b-hydroxybutyrate pro-
duced by peripheral fat metabolism can be used by brain to
supplement glucose as an energy source. Ketones enter brain through
monocarboxylic transporters (MCTs) at the blood–brain barrier at a
rate influenced by both blood ketone concentration and MCT expres-
sion level (Halestrap & Price, 1999). Fasting increases MCT expression
at the blood–brain barrier, and ketones can provide the majority of
brain energy substrate under starvation conditions. MCTs also trans-
port lactate and pyruvate. Blood-derived lactate provides supports
10% of brain metabolism under basal plasma lactate conditions of
1.0 mmol/L, and higher percentages at supra-physiological plasma
lactate concentrations (Boumezbeur et al., 2010).
3 | MICROGLIA UTILIZE BOTH OXIDATIVE
AND GLYCOLYTIC ENERGY METABOLISM
Direct data on the relative contributions of glycolytic and oxidative
ATP production in microglia in situ are not available. As an indirect
assessment, we compared the mRNA levels of genes related to
energy metabolism in neurons, microglia and astrocytes, using a
database of cell-type specific gene expression generated from
acutely dissociated mouse brain (Zhang et al., 2014), (Figure 1,
Tables 1 and 2). This analysis shows that microglia express the full
complement of genes required for both glycolytic and oxidative
energy metabolism. Perhaps surprisingly, the quantitative expression
of genes involved in oxidative metabolism is, in aggregate, compara-
ble or higher in microglia than in neurons and astrocytes (Figure 1).
These gene expression data do not necessarily indicate the relative
rates and routes of energy metabolism in these cell types, but they
do confirm the capacity of microglia in situ to generate ATP by both
glycolytic and oxidative pathways.
Microglia express several glucose transporters, with GLUT3
(SLC2A3) being the major isoform (Kalsbeek, Mulder, & Yi, 2016).
GLUT3 is a passive, facilitated glucose transporter, and it is also the
dominate isoform expressed by neurons (Vannucci, Maher, & Simp-
son, 1997). Unlike other cell types in brain, microglia also express
GLUT5 (SLC2A5; Payne, Maher, Simpson, Mattice, & Davies, 1997;
see also Table 2). GLUT5 is classified as a fructose transporter
because it has a high affinity for fructose and relatively low affinity
for glucose. As fructose is present only at low concentrations in
brain, the physiological role of this transporter on microglia remains
obscure (Douard & Ferraris, 2008). Microglia are also able to take up
ketones and lactate, through the monocarboxylic transporters MCT1
and MCT2 (Moreira et al., 2009). The extent to which these non-
glucose substrates fuel microglial function is unknown, but ketones
have been shown to influence microglial function (as further
described below).
Quiescent microglia are thought to rely primarily upon oxida-
tive phosphorylation for ATP production (Bernhart et al., 2010;
Chenais, Morjani, & Drapier, 2002; Moss & Bates 2001; Won
et al., 2012). Activated microglia in culture increase lactate pro-
duction, decrease mitochondrial oxygen consumption, and
decrease mitochondrial ATP production, indicative of an increased
reliance on glycolysis (Gimeno-Bayon, Lopez-Lopez, Rodriguez, &
Mahy, 2014; Voloboueva, Emery, Sun, & Giffard, 2013). A switch
from oxidative phosphorylation to aerobic glycolysis has likewise
been shown to occur in macrophages as they transition between
resting and activated states (Galvan-Pena & O’Neill, 2014). How-
ever, the concept that activated microglia shift to glycolytic
energy production does not cleanly fit with observations of micro-
glial mitochondrial density. In cultured rat microglia, stimulation by
lipopolysaccharide (LPS) and interferon-g increases the abundance
of microglial mitochondria (Banati et al., 2004; Ferger et al.,
2010). Microglial activation is also associated with de novo syn-
thesis of mitochondrial translocator protein (Venneti, Lopresti, &
Wiley, 2006), suggesting that the increased mitochondrial number
is attributable to mitochondrial biogenesis rather than mitochon-
drial fission.
While it seems reasonable to assume that impaired capacity
for energy production would influence microglial function, there is
only limited information available in this area. Reduced substrate
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availability has been shown to induce stress granule formation in
cultured microglia. Cytosolic stress granules are irregular com-
plexes of RNA and RNA binding proteins (Hanson & Mair, 2014;
Krisenko et al., 2015), and in microglia they stimulate the produc-
tion of reactive oxygen and nitrogen species through activation of
spleen tyrosine kinase and its downstream substrates such as NF-
jB (Ghosh & Geahlen, 2015). The mitochondrial toxins carbon
monoxide, rotenone, and 3-nitroproprionate each influence LPS-
induced cytokine production by cultured microglia (Ferger et al.,
2010; Wilson et al., 2017); however, glycolytic capacity can often
fully compensate for impaired mitochondrial ATP production in cul-
tured cells, and consequently the effects of these toxins may be
indirect. More direct evidence that bioenergetic capacity can influ-
ence microglial function comes from studies of mice deficient in
triggering receptor expressed on myeloid cells-2 (TREM2). TREM2
is a microglial surface receptor that is required for normal micro-
glial responses to dead and damaged cells. TREM2 deficient micro-
glia in mouse brain exhibit, in addition to functional impairment, a
reduced mitochondrial mass, increased AMPK phosphorylation
(indicating low energy status), and increased autophagy (Ulland
et al., 2017). Manipulations that reconstitute TREM2 intracellular
signaling or support ATP synthesis reverse all of these abnormal-
ities, suggesting that the functional impairment stems from bioen-
ergetic compromise.
4 | GLUCOSE AND MICROGLIAL ROS
PRODUCTION
Independent of its role in energy metabolism, glucose is also required
for the quenching of ROS and for repairing oxidative damage to cells
FIGURE 1 Comparative expression profile analysis of genes related to oxidative and glycolytic metabolism in astrocytes, neurons and
microglia. The FPKM (Fragments Per Kilobase of transcript sequence per Million mapped fragments) data, previously reported in (Zhang
et al. 2014) and available at http://web.stanford.edu/group/barres_lab/brain_rnaseq.html, was exported and analyzed using a cut-off value
of 5 FPKM in at least one sample. Stacked bar columns show the expression of oxidative (a) and glycolytic (b) metabolism-related genes in
astrocytes, neurons and microglia. Colors represent individual genes, listed in Tables 1 and 2. (c) Canonical pathways related to the oxidative
and glycolytic metabolism in each cell type as assigned by Ingenuity Pathway Analysis software (IPA) (http://www.ingenuity.com/index.
html). Horizontal axis shows the—log(P value) for the pathways in each cell type, based on the probability that genes in each cell type were
included in the predefined IPA canonical pathways by true association as opposed to random chance. Dotted line shows P 5 .05
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TABLE 1 Expression of genes related to oxidative metabolism in
astrocytes, neurons, and microglia
Function Gene
Expression (FPKM)
Astrocytes Neurons Microglia
Acetyl-CoA
biosynthesis
Acaa2 32.1 3.5 18.1
Acox1 53.7 35.2 17.9
Acox3 7.1 4.4 31.8
Cpt1a 49.5 11.7 19.5
Cpt1c 15.8 26.4 2.5
Cs 94.1 61.5 28.4
Pdha1 49.6 74.4 13.2
Pdhb 19.0 27.5 11.1
Pdhx 12.8 11.8 4.1
Slc25a20 14.2 4.7 7.5
Oxidative
phosphorylation
Atp5a1 121.1 231.8 195.3
Atp5b 215.6 384.8 280.6
Atp5c1 52.0 81.5 80.7
Atp5d 51.4 105.1 127.3
Atp5e 63.4 90.2 146.4
Atp5f1 24.2 44.1 15.8
Atp5g1 3.1 11.1 5.1
Atp5g2 21.9 31.5 80.8
Atp5g3 143.3 243.0 110.0
Atp5h 4.7 7.7 8.2
Atp5j 43.5 75.8 36.4
Atp5j2 34.5 83.1 97.8
Atp5l 8.4 19.0 9.9
Atp5o 25.0 58.6 42.0
Atp5s 4.5 6.6 1.4
Atpaf2 9.1 7.7 7.0
Cox10 11.8 4.0 3.4
Cox11 7.8 6.2 1.1
Cox17 13.5 12.4 26.5
Cox4i1 120.8 255.3 446.3
Cox5a 53.2 109.8 61.4
Cox6a1 83.7 160.6 189.2
Cox6a2 0.1 1.2 7.2
Cox6b1 89.7 187.9 210.8
Cox6c 49.8 74.9 62.8
Cox7a2 40.4 85.5 58.7
Cox7a2l 20.6 49.4 140.0
Cox7b 11.5 29.5 10.3
(Continues)
TABLE 1 (Continued)
Function Gene
Expression (FPKM)
Astrocytes Neurons Microglia
Oxidative
phosphorylation (cont.)
Cox8a 123.0 191.0 228.0
Ndufa1 21.7 49.5 34.5
Ndufa10 21.6 31.8 30.3
Ndufa11 5.4 12.0 7.5
Ndufa12 8.8 13.3 10.6
Ndufa13 17.7 32.5 36.2
Ndufa2 37.5 54.7 80.0
Ndufa3 46.7 60.6 100.7
Ndufa4 75.4 167.3 64.6
Ndufa5 16.7 37.0 11.0
Ndufa6 35.2 60.5 78.4
Ndufa7 35.3 53.4 74.2
Ndufa8 18.2 37.4 32.5
Ndufa9 28.3 42.2 40.9
Ndufb10 31.6 62.5 45.5
Ndufb11 23.6 32.1 42.9
Ndufb2 29.6 80.8 37.1
Ndufb3 21.8 52.5 25.5
Ndufb4 6.7 10.4 12.1
Ndufb5 27.0 43.6 34.1
Ndufb6 33.8 65.4 25.6
Ndufb7 23.4 45.1 68.8
Ndufb8 30.3 74.9 79.7
Ndufb9 46.3 70.1 60.4
Ndufs1 31.8 22.3 7.5
Ndufs2 43.8 56.6 67.7
Ndufs3 8.0 9.5 8.0
Ndufs4 14.0 25.1 16.0
Ndufs6 14.4 18.8 16.5
Ndufs7 31.2 44.3 46.7
Ndufs8 21.0 27.9 76.3
Ndufv1 27.3 44.8 37.7
Ndufv2 22.7 37.4 16.6
Ndufv3 23.1 58.7 51.3
Slc25a14 5.4 9.4 1.7
Slc25a27 4.2 27.0 0.3
Uqcrb 8.4 11.6 6.1
Uqcrc1 43.7 64.6 92.4
Uqcrc2 50.2 62.8 36.2
(Continues)
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through glutathione and thioredoxin—coupled pathways. This is
because glucose is the exclusive substrate for the hexose monophos-
phate shunt (Figure 2). NADPH produced by the hexose monophos-
phate shunt is required by glutathione reductase to convert oxidized
glutathione (GSSG) back to reduced glutathione (GSH), the major thiol
anti-oxidant in brain, and likewise required for reducing thioredoxin
to its active form (Mustacich & Powis, 2000).
TABLE 1 (Continued)
Function Gene
Expression (FPKM)
Astrocytes Neurons Microglia
Oxidative
phosphorylation (cont.)
Uqcrfs1 49.6 63.3 46.2
Uqcrh 56.6 94.1 116.7
Uqcrq 52.3 75.2 89.2
Oxidative phosphorylation,
TCA cycle
Sdha 46.1 45.6 36.1
Sdhb 34.6 55.0 82.7
Sdhc 51.8 56.2 66.3
Sdhd 43.3 51.7 54.0
Radicals detoxification Gsr 7.7 7.6 7.3
Nfe2l2 11.9 2.1 55.7
Nfkb1 7.3 1.9 51.0
Nfkbia 49.6 13.1 720.1
Sod1 22.6 33.4 33.5
Sod2 14.0 21.6 14.0
Sod3 9.1 0.4 0.8
Txn2 28.8 42.6 45.8
Txnip 27.5 5.0 358.5
TCA cycle Aco1 23.3 7.4 11.6
Aco2 31.6 38.5 29.8
Idh1 82.8 38.6 8.4
Idh2 39.5 10.3 77.2
Mdh1 44.7 105.3 59.8
Mdh2 62.0 120.3 85.4
Ogdh 15.4 16.9 16.6
Ogdhl 13.6 4.3 1.1
Mut 10.2 3.4 1.3
Pck2 2.6 4.7 10.9
Pcx 32.8 6.4 4.2
Slc25a1 24.6 43.7 30.4
Slc25a10 4.0 2.4 19.5
Slc25a11 19.8 38.1 55.6
Slc25a12 17.0 30.9 4.9
TABLE 2 Expression of genes related to glycolytic metabolism in
different astrocytes, neurons, and microglia
Function Gene
Expression (FPKM)
Astrocytes Neurons Microglia
Glucose
transporters
Slc2a1 56.4 11.4 46.6
Slc2a3 1.7 32.9 5.4
Slc2a5 0.2 0.3 223.0
Glycogen
degradation
Agl 13.7 4.0 1.2
Gaa 25.6 33.6 38.6
Mtap 5.0 2.1 2.8
Pgm1 6.1 6.5 6.0
Pgm2 27.0 10.7 8.5
Pygb 111.0 31.7 19.8
Pygm 5.6 0.7 9.6
Glycolysis Aldoa 109.8 270.5 271.6
Aldoart1 6.2 13.0 14.6
Aldoart2 3.8 8.7 11.9
Aldoc 512.1 28.2 42.6
Bpgm 18.0 13.3 4.6
Eno1 2.4 6.8 14.5
Eno2 5.0 82.6 35.3
Eno3 6.1 5.5 19.6
Gapdh 40.2 73.4 79.9
Gpi1 26.6 53.6 49.1
Hk1 14.2 41.6 13.4
Hk2 4.5 0.4 62.3
Hk3 0.1 0.2 64.0
Pfkl 12.9 20.0 37.5
Pfkm 73.9 47.9 8.9
Pfkp 8.9 31.6 2.4
Pgam1 40.1 79.1 75.8
Pgk1 18.4 22.1 18.3
Pgm2l1 1.1 14.6 0.7
Pkm2 53.8 83.6 153.6
Tpi1 39.7 84.2 95.1
Glycolysis
(anaerobic)
Ldha 42.4 68.6 105.9
Ldhb 62.1 34.7 228.4
Glycolysis
(regulators)
Pfkfb2 23.5 14.6 1.5
Pfkfb3 60.3 5.3 77.2
Pfkfb4 12.5 4.4 9.7
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Glucose is also used by cells to generate ROS. One way this
occurs is by fueling the mitochondrial electron transport chain.
Glucose is normally the origin of the vast majority of reducing
equivalents (electrons) passing through the mitochondrial electron
transport chain in CNS tissues (Figure 2). Reducing equivalents
carried by NADH enter the mitochondrial electron transport chain
and normally pass all the way to mitochondrial complex IV (cyto-
chrome C oxidase) during oxidative ATP production, where they
reduce molecular oxygen (O2) to H2O. However, it is possible for
electrons to escape from the electron transport chain or reduced
mitochondrial enzymes to form superoxide (O:2); (Adam-Vizi,
2005; Nicholls & Ferguson, 2013; Starkov et al., 2004). The rate
at which this process generates superoxide in healthy cells is con-
sidered very low, far below the early estimate of 2% of respira-
tory oxygen flux obtained using isolated (cell-free) mitochondria
(Boveris, 1977). However, this rate becomes appreciable during
ischemia-reperfusion (Niatsetskaya et al., 2012), in damaged or
defective mitochondria (Hayashi & Cortopassi, 2015), and in the
presence of mitochondrial toxins (Adam-Vizi, 2005; Nicholls &
Ferguson, 2013).
A second way that glucose fuels ROS production is through gen-
erating NADPH (via the hexose monophosphate shunt) for enzy-
matic production of nitric oxide and superoxide (Figure 2). Microglial
inducible nitric oxide synthase (iNOS) uses NADPH and L-arginine as
substrates to generate nitric oxide (Possel, Noack, Putzke, Wolf, &
Sies, 2000). Nitric oxide is non-polar, lipid permeable, and has a rela-
tively long half-life and diffusion distance in brain (Pacher, Beckman,
& Liaudet, 2007). Superoxide, by contrast, is polar, largely lipid
impermeable, and has a relatively short half-life and diffusion dis-
tance (Pacher et al., 2007). Neither of these ROS are intrinsically
highly cytotoxic, but both can be further metabolized to produce
highly reactive and cytotoxic species such as hypochlorous acid, per-
oxynitrite, and hydroxyl radical.
Superoxide is enzymatically produced by NADPH oxidase, a multi-
subunit protein complex with several isoforms distinguished on the
basis of their catalytic domains: NOX1–NOX5, DUOX 1, and DUOX2.
Most cell types express one or more forms of NADPH oxidase and gen-
erate superoxide as a local signaling molecule (Bedard & Krause, 2007).
Cells of immune lineage, including microglia, express predominately the
NOX2 isoform and use superoxide (in conjunction with nitric oxide or
HCl to kill invading pathogens (Kauppinen et al., 2008; Schieber &
Chandel 2014). NOX2 generates superoxide by the transfer of electrons
to molecular oxygen on one side of a membrane, while oxidizing
NADPH to NADP1 and H1 on the other side. In stimulated phagocytes,
the rate of O2 consumption by NOX2 can exceed the normal rate of O2
consumption by mitochondria, a process termed as “respiratory burst”.
This rapid superoxide production requires the continuous metabolism of
glucose by the hexose monophosphate shunt for supply of NADPH
substrate (Cohen & Chovaniec, 1978; Decoursey & Ligeti, 2005).
Whether microglia are likewise capable of very rapid superoxide
production has not been established, but it is nevertheless likely that
the ability of microglia to generate superoxide is dependent upon glu-
cose availability. To directly test this idea, we treated primary mouse
microglial cultures with bacterial LPS to activate NOX2, and evaluated
superoxide production in the presence and absence of glucose in the
medium (Figure 3). The medium was supplemented with glutamine as
an energy source to prevent ATP depletion. LPS induced a robust
superoxide production in medium containing glucose (4 mM), as
detected by dihydroethidium oxidation. By contrast, superoxide produc-
tion was negligible in medium that did not contain glucose (Figure 3).
The link between glucose and ROS production may also be rele-
vant to the deleterious effects of elevated blood glucose
FIGURE 2 Glucose fuels both ROS scavenging and ROS production. Glucose metabolized through the hexose monophosphate shunt
provides reducing equivalents for regenerating NADPH from NADP1. NADPH in turn is used by glutathione reductase (GR) to regenerate
glutathione (GSH) from glutathione disulfide (GSSG). GSH is used for enzymatic and non-enzymatic scavenging of ROS, and for repair of
proteins that have been oxidized by ROS. However, NADPH derived from the hexose monophosphate shunt is also a requisite cofactor for
the production of nitric oxide (NO.) by nitric oxide synthase and superoxide (O:2) by NADPH oxidase (NOX). Glucose metabolized through
glycolysis provides reducing equivalents for regenerating NADH from NAD1. These reducing equivalents (electrons) normally transit the
mitochondrial electron transport chain in the process of generating CO2 and ATP, but under some conditions a substantial fraction of these
electrons are instead captured by oxygen to form superoxide. (Adapted from (Robbins & Swanson, 2014)
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(hyperglycemia) in brain ischemia-reperfusion (Bruno et al., 1999;
Martini & Kent, 2007; Myers & Yamaguchi, 1977; Parsons et al.,
2002; Ribo et al., 2005). A widely cited mechanism by which hyper-
glycemia can exacerbate brain injury is by increasing lactic acid pro-
duction and thereby reducing pH in hypoxic tissue (Plum, 1983);
however, elevated glucose exacerbates ischemic injury even when
acidosis is minimal (D’Alecy, Lundy, Barton, & Zelenock, 1986; Park,
Chang, & Lee, 2001; Venables, Miller, Gibson, Hardy, & Strong,
1985) and in hypoxic brain slices where pH is tightly controlled
(Newell, Barth, Papermaster, & Malouf, 1995; Rytter, Cronberg,
Asztely, Nemali, & Wieloch, 2003). Hyperglycemia increases super-
oxide production from neurons during ischemia-reperfusion, and
NOX2 inhibition prevents both the increased superoxide production
and increased neuronal death that would otherwise occur (Suh et al.,
2008; Won, Tang, Suh, Yenari, & Swanson, 2011). It remains to be
established if the superoxide production by microglia in the later,
inflammatory stage of ischemic injury is likewise increased by high
blood glucose concentrations.
5 | ENERGY METABOLISM AFFECTS PRO-
INFLAMMATORY GENE EXPRESSION BY
MICROGLIA
Inflammatory responses are influenced at the gene transcription level
by factors that affect cellular bioenergetic state, such as caloric restric-
tion, ketogenic diet, and the glycolytic inhibitor 2-deoxyglucose (2DG;
FIGURE 3 Superoxide production by microglia requires glucose. (a) LPS induced a robust superoxide production in the microglia in control
medium, but not in glucose-free medium. The fluorescent red signal is produced by oxidized dihydroethidium. Lack of signal in cultures co-treated
with NOX inhibitor apocynin (Apo, 10 mM) confirms superoxide as the oxidant species. (b) Quantified data. n 5 3, **P < .01; means 6 SEM. (c)
Measures of cellular ATP in cells treated as in A showed no significant decrement in the glucose-free conditions. The mitochondrial inhibitor azide
(10 lM) was used as a positive control in presence of glucose. n 5 3, **P < .01 versus control; means 6 SEM. Primary microglia were prepared as
described (Saura, Tusell, & Serratosa, 2003). Experiments were done using DMEM containing no phenol red, 4 mM glutamine, and either 4 or 0 mM
glucose. LPS was used at 500 ng/ml. Cells were incubated with dihydroethidium (DHE; 10 mM) for 30 min, then fixed with 4% formaldehyde. Micro-
glia were identified using antibody to Iba1 (ab10709, Abcam) and green fluorescent secondary antibody. Cell nuclei are labelled with DAPI (blue).
Superoxide production was quantified as described (Brennan et al., 2009). For ATP measurements, cells were lysed after 30 min intervals using
detergent supplied by the Abcam luminescence ATP detection assay kit (ab113849). Luminescence was measured in parallel with ATP standards
treated identically. Cultures were visually inspected to confirm no significant well-to-well variation in cell number. Data were obtained from 3 inde-
pendent experiments, each with 2–3 internal replicates. Statistical comparisons were made by ANOVA with Bonferroni’s test. All studies were
approved by the San Francisco Veterans Affairs Medical Center animal studies committee
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Goth, 1959; Longo & Mattson, 2014). Calorie restriction, ketogenic
diet, and 2DG each produce a ketogenic state in which glucose utiliza-
tion is suppressed, and they also reduce inflammation, tissue loss, and
functional impairment after brain injury (Appelberg, Hovda, & Prins,
2009; Gasior, Rogawski, & Hartman, 2006; Loncarevic-Vasiljkovic et al.,
2012; Tu, Lu, Huang, Ho, & Chou, 2012; Wang et al., 2009; Yu & Matt-
son, 1999). Examples of this are shown in Figure 4. In these studies,
LPS was used as an inflammatory stimulus, and the reduced glycolytic
flux resulting from caloric restriction was mimicked by the glycolytic
inhibitor 2DG (Garriga-Canut et al., 2006; Yao, Chen, Mao, Cadenas, &
Brinton, 2011). Systemic (intraperitoneal) administration of LPS to rats
induced a robust activation of brain microglia, and this was attenuated
by co-administration of 2DG (Figure 4a). In organotypic brain slice cul-
tures (Figure 4b), 2DG likewise suppressed the effect of LPS on micro-
glial activation and on the expression of iNOS, a hallmark of
inflammatory activation in microglia and macrophages (Forstermann &
Kleinert, 1995). Primary microglial cultures similarly showed an attenu-
ated response to LPS in the presence of 2DG (Figure 4c), thus confirm-
ing that the effects of LPS and 2DG on microglia are not dependent
upon indirect, systemic effects of these agents.
Recent studies have identified several mechanisms by which glu-
cose levels can influence pro-inflammatory gene transcription. One of
these mechanisms involves the formation of advanced glycation end
products (AGE), which are modifications of proteins and lipids resulting
from non-enzymatic reactions with sugars. AGE formation is generally
a slow process, but is accelerated under high glucose levels. Microglia
express receptors for advanced glycation end-products, which stimu-
late pro-inflammatory signaling pathways when activated (Bianchi,
Giambanco, & Donato, 2010; Chen et al., 2017). Glycolytic rate (though
not necessarily glucose levels per se) can also influence formation of
FIGURE 4 Glucose metabolism affects microglial activation and ROS production at the transcriptional level. (a) Immunostaining for CD11b
identifies activated microglia in rat hippocampus. CD11b expression was increased 24 hr after intraperitoneal injection with LPS (10 mg/kg).
The increase was attenuated by co-injection with the glycolytic inhibitor 2-deoxyglucose (2DG; 100 mg/kg). Scale bar 5 100 mm. **P < .01,
n 5 6. (b) Immunostaining for Iba1 and iNOS identify activated microglia in mouse hippocampal slice cultures after 24 hr incubation with
LPS (10 lg/ml) or LPS 1 2DG (1 mM). Scale bar 5 100 mm; n  3, *P < .05. Culture medium for contained 6 mM glutamine and 5 mM glu-
cose. (c) Effects of 1 mM 2DG on LPS-induced iNOS transcript and protein expression in microglial cultures. n 5 5; *P < .05, **P < .01.
Data are means 6 SEM. Figure adapted from (Shen et al., 2017)
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NLRP1 and NLRP3 inflammasomes. Inflammasomes are responsible for
caspase 1 activation, which is required for maturation and secretion of
IL-1b and other cytokines (Franchi, Eigenbrod, Munoz-Planillo, &
Nunez, 2009). Increased glycolytic rate facilitates NLRP3 assembly in
macrophages, (Moon et al., 2015; Xie et al., 2016), by a mechanism
that remains to be established. In brain, NLRP3 inflammasomes are
FIGURE 5.
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found in microglia but not in astrocytes (Gustin et al., 2015). Intermit-
tent fasting was shown to suppress post-ischemic expression of inflam-
masomes, and this effect was associated with reduced Il1-b and
reduced NF-jB signaling in the post-ischemic brain (Fann et al., 2014).
An additional, more direct way that glucose metabolism exerts
transcriptional control over microglial activation is through an NADH-
sensitive co-repressor termed C-terminal binding protein (CtBP). Fac-
tors that slow glucose flux through glycolysis, such as reduced glucose
availability or glycolytic inhibitors, reduce NADH levels and thereby
reduce NADH:NAD1 ratio. By contrast, factors that slow oxidative
metabolism, such as hypoxia and mitochondrial inhibitors, have the
opposite effect (Figure 5a). The resulting relative changes in NADH are
several hundred-fold greater than the reciprocal changes in NAD1
because the cytosolic NADH:NAD1 ratio is normally in the range of
1:700 (Ying, 2008). For this reason, changes in cytosolic NADH levels
provide a highly sensitive measure of changes in glycolytic flux.
The CtBPs are among a very limited number of NADH—sensitive
proteins known to influence gene transcription (Ghosh, George, Roy,
Ramachandran, & Kolthur-Seetharam, 2010). CtBP in its monomeric
form suppresses the activity of the acetyltransferase p300/CBP (Kim,
Cho, Kim, & Youn, 2005), which acetylates both histones and the pro-
inflammatory transcription factor, NF-jB (Chen, Mu, & Greene, 2002).
Increased NADH levels promote the formation of CtBP dimers, and
thereby modulate CtBP association with its binding partners (Zhang,
Piston, & Goodman, 2002). In microglia and the macrophage
RAW264.7 cell line, glucose flux was shown to regulate the expression
of iNOS and other pro-inflammatory genes by a mechanism involving
CtBP sensing of cytosolic NADH levels (Shen et al., 2017). This mecha-
nism may more generally couple glucose metabolism to innate immune
reactivity (Figure 5c).
6 | DIRECT EFFECTS OF KETONES ON
MICROGLIAL ACTIVATION
Sustained reductions in blood glucose levels lead to a rise in circulat-
ing ketones, as peripheral fat is metabolized to acetoacetate,
b-hydroxybutyrate, and their breakdown product acetone. A keto-
genic state is common in animals in the wild, and occurs in humans
during fasting and extended exercise. Fasting and ketogenic diet
have well-established anti-inflammatory effects, including
suppression of microglial activation (Fann et al., 2014; Gasior et al.,
2006; Longo & Mattson, 2014). These effects are mediated in part
by direct signaling by ketones on microglia and macrophages.
b-Hydroxybutyrate activates G-protein-coupled receptors 109A
(GPR109A) and inhibits histone de-acetylases (Huang et al., 2017;
Newman & Verdin, 2014; Rahman et al., 2014). In microglia, the acti-
vation of GPR109A by b-hydroxybutyrate attenuates NF-kB signal-
ing and pro-inflammatory cytokine production (Fu et al., 2015).
Activation of GPR109A also promotes a neuroprotective phenotype
in microglia/macrophages, and in a mouse stroke model the benefi-
cial and anti-inflammatory effects of ketogenic diet are lost in mice
lacking the GPR109A receptor. Microglia and macrophages also
express other metabolite receptors in addition to GPR109A, but the
effects on these on microglia function remain to be established.
7 | CONCLUSIONS
As “sentinels” of the nervous system, it is fitting that microglia respond
to changes in brain metabolism. It has been recognized for decades
that bioenergetic factors influence innate immune responses (Goth,
1959), but only recently have some the mechanisms that underlie these
effects been identified. As our understanding of microglial activation
becomes more nuanced and complete, we can likely expect to find
additional links between bioenergetic factors and specific aspects of
activation, such as specific gene expression patterns or morphological
changes. However, microglia are normally in a state that is “quiescent”
but not inert, as they perform trophic, signaling, and other functions
important to normal brain homeostasis, and virtually nothing is yet
known about how bioenergetic factors may influence these basal
microglial functions. Moreover, most of what is now known about bio-
energetic influences on microglia comes from studies performed with
dissociated cultures and thus require validation in more complex sys-
tems. Microglial cultures do not always reflect the properties of micro-
glia in situ, and do not account for the complexity inherent in multiple
interacting cell types simultaneously experiencing and responding to
bioenergetic changes.
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FIGURE 5 NADH and CtBP mediate coupling between glucose metabolism and gene transcription. (a) Factors that slow glucose flux
through glycolysis, such as reduced glucose availability or glycolytic inhibitors, reduce NADH levels and thereby reduce NADH:NAD1 ratio,
whereas factors that slow oxidative metabolism, such as hypoxia and mitochondrial inhibitors, have the opposite effect. Lactate
dehydrogenase (LDH) maintains the lactate:pyruvate ratio in equilibrium with the cytosolic NADH:NAD1 ratio. In the experiments shown,
glutamine provided a-ketoglutarate to fuel mitochondrial ATP production in the absence of glycolysis. (b) The lactate:pyruvate ratio provides
an index of the cytosolic NADH:NAD1 ratio in cells treated with glycolytic inhibition (2DG, 1 mM 2-deoxyglucose; 0 Glu, glucose-free
medium) or mitochondrial inhibitors (CoCl2, 200 mM cobalt chloride; antimycin, 1 mM antimycin (a). n 5 4; *P < .05 versus control. (c) LPS-
induced iNOS expression was suppressed in RAW267.4 cells treated with 1 mM 2DG or glucose-free medium, and was increased in cells
treated with the CoCl2. n 5 4; *P < .05 versus control. Error bars show SEM. (d) CtBP normally binds and inhibits p300 acetylase. NADH
promotes CtBP dimerization and resultant release of p300 from CtBP. Unbound p300 acetylates the p65 subunit of NF-jB to promote NF-
jB transcriptional activity. Fasting, ketogenic diet, and glycolytic inhibition reduce NADH levels and thereby reduce CtBP dimerization and
increase CtBP repression of p300 activity. Hypoxia, hyperglycemia, and mitochondrial dysfunction have the reverse effect. Panels a, b, and
c are from (Shen et al., 2017)
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